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Abstract
Radiotherapy induces immune-related responses in cancer patients by various mechanisms. Here, we investigate the
immunomodulatory role of tumor-derived microparticles (TMPs)—extracellular vesicles shed from tumor cells—following
radiotherapy. We demonstrate that breast carcinoma cells exposed to radiation shed TMPs containing elevated levels of
immune-modulating proteins, one of which is programmed death-ligand 1 (PD-L1). These TMPs inhibit cytotoxic T
lymphocyte (CTL) activity both in vitro and in vivo, and thus promote tumor growth. Evidently, adoptive transfer of CTLs
pre-cultured with TMPs from irradiated breast carcinoma cells increases tumor growth rates in mice recipients in comparison
with control mice receiving CTLs pre-cultured with TMPs from untreated tumor cells. In addition, blocking the PD-1-PD-L1
axis, either genetically or pharmacologically, partially alleviates TMP-mediated inhibition of CTL activity, suggesting that
the immunomodulatory effects of TMPs in response to radiotherapy is mediated, in part, by PD-L1. Overall, our findings
provide mechanistic insights into the tumor immune surveillance state in response to radiotherapy and suggest a therapeutic
synergy between radiotherapy and immune checkpoint inhibitors.
Introduction
Radiotherapy is currently one of the leading treatment
options for cancer patients. Ionizing radiation applied
locally to the tumor site causes DNA damage and sub-
sequent cell death [1]. A growing number of studies have
shown that in addition to the local effects at the irradiated
tumor site, radiation activates several systemic biological
responses, such as adaptive and innate immune-related
activities that affect tumor progression [2–4]. For exam-
ple, preclinical studies reported that macrophages
exposed to radiation promote metastasis [5–7]. Accord-
ingly, the elimination of macrophages from irradiated
hosts inhibits tumor growth and metastasis [5]. In addi-
tion, Ahn et al. reported that myeloid cells in tumor-
bearing mice home to the irradiated tumor site and
contribute to tumor angiogenesis and subsequent re-
growth [8]. Thus, there are systemic host responses fol-
lowing radiotherapy that contribute to tumor re-growth
and subsequent resistance [9].
It has been shown that cells of the adaptive immune
system play a role in modulating treatment efficacy in
irradiated tumors. For example, following radiation, dying




1 Cell Biology and Cancer Science, Rappaport Faculty of Medicine,
Technion, Haifa, Israel
2 Oncology Institute, Radiation Oncology Unit, Rambam Health
Care Campus, Haifa, Israel
3 Department of Medical Oncology, University of Groningen,
University Medical Center Groningen, Groningen, The
Netherlands
4 Division of Cancer Epidemiology & Genetics, Integrative Tumor
Epidemiology Branch, National Cancer Institute, National Institute
of Health, Bethesda, MD, USA
5 Sunnybrook Health Sciences Centre, Toronto, ON, Canada
Supplementary information The online version of this article (https://
doi.org/10.1038/s41388-019-0971-7) contains supplementary















tumor cells stimulate dendritic and cytotoxic T-cell activity
directed against viable tumor cells [10, 11]. Thus, tumors or
metastatic sites that are outside of the irradiated field may
respond positively to the radiation; however, such antitumor
effects are rarely reported in the clinic. This phenomenon,
termed the “abscopal effect”, is due to extensive inflam-
mation and activation of immune cells as a result of radia-
tion [12, 13]. Contrarily, radiotherapy can lead to
myelosuppression that counteracts the benefit of activated
immune cells [14, 15]. This cross-talk between immune
cells and the irradiated site has provided a rationale for
combining radiotherapy with immunotherapy, including
immune checkpoint inhibitors [16–18]. Yet, the systemic
effects generated in response to radiotherapy and immu-
notherapy are not fully explored.
The mobilization and trafficking of bone marrow-
derived cells (BMDCs) are often affected by extracellular
microvesicles (EVs) [19, 20]. EVs serve as a route of
communication between cells at distant sites by transfer-
ring microRNA, proteins, and lipids, as demonstrated
mainly in preclinical studies [20, 21]. EVs are classified
according to their size and the mechanism by which they
are formed. Exosomes, which are 30–120 nm in size,
originate from the internal compartment of a cell, whereas
microparticles (MPs), which are 0.1–1.0 µm in size, are
generated from the outer cytoplasmic membrane blebbing
or shedding, as was previously characterized by trans-
mission electron microscopy [22]. In cancer, tumor-
derived microparticles (TMPs) have been associated
with therapy resistance. Specifically, they induce inflam-
mation, angiogenesis, and even metastasis (for review see
refs. [20, 23]). Moreover, TMPs and exosomes promote
the mobilization of BMDCs from the bone marrow com-
partment and their homing to tumor or metastatic sites
[19, 24], an effect that is enhanced in response to che-
motherapy [19, 25]. Importantly, recent studies demon-
strated that EVs may express programmed death-ligand 1
(PD-L1), thus contributing to immune evasion by PD-L1-
dependent T-cell inhibition [26, 27]. However, the role of
TMPs in response to radiation and their possible con-
tribution to immune cell activity at the irradiated tumor
sites has not been studied.
Here, we show that TMPs from irradiated breast car-
cinoma cells contain high levels of an array of immuno-
suppressive proteins in comparison with TMPs derived
from untreated cells. These TMPs modulate the immune
system, in part via PD-L1, resulting in enhanced tumor
growth. Our study suggests that the expression of PD-L1
on TMPs could be useful as a possible biomarker to
identify patients who are likely to benefit from the
combination of radiotherapy with immune checkpoint
therapy.
Results
TMPs from irradiated breast carcinoma cells are
associated with immune modulation activity
We have previously shown that chemotherapy increases the
production of TMPs originating from breast carcinoma cell
lines, as well as from breast cancer patients [19]. To
determine whether TMP production is similarly affected by
radiotherapy, EMT/6, 4T1, PyMT, E0771, and DA3 breast
carcinoma cell cultures were exposed to a single fraction of
2 Gy or 6 Gy radiation, in accordance with clinically used
doses. Forty-eight hours later, TMPs were collected from
the conditioned medium and quantified by flow cytometry,
using a method previously described in ref. [19]. With the
exception of E0771 cells exposed to 6 Gy radiation, TMP
production did not significantly change in response to the
tested radiation doses in all other cell lines (Fig. S1A).
Next, to rule out the possibility that apoptotic bodies are
generated in response to a single-dose radiation, we asses-
sed cell viability, early, and late apoptosis states in EMT6,
4T1, and PyMT cell lines 48 h after irradiation using
Annexin V and 7-AAD staining. Cell viability did not
significantly change at this time point, except for 4T1 cells
that exhibited a slight increase in necrotic cells at a radiation
dose of 6 Gy, but not 2 Gy (Fig. S1B). These results rule out
the possibility that quantification of TMPs originating from
the control and 2 Gy irradiated cells is affected by the
presence of apoptotic bodies in our experimental setting.
We sought to determine whether the physical properties
of TMPs are modified in response to radiotherapy. To this
end, we assessed whether radiotherapy affects the size of
TMPs using NanoSight NS300 analyzer. There were no
substantial changes in TMP size between the different
groups in any of the breast carcinoma cell lines tested (Fig.
S1C). These results indicate that radiotherapy does not
affect the physical properties of TMPs, at least in terms of
size and therefore TMPs are probably characterized as
previously described [28–33].
We next sought to determine whether radiotherapy
affects the physiological properties of TMPs. To test this,
we characterized the protein content of TMPs originating
from the control or irradiated EMT/6 and PyMT cells using
high-resolution mass spectrometry-based proteomic analy-
sis, as described in the Materials and methods section. This
analysis revealed an increased total protein content in TMPs
from cells exposed to radiotherapy in comparison with
TMPs from untreated cells in both cell lines tested (Table
S1 for the entire proteomic data and Fig. S2). Principal
component analysis further highlighted the large variation
in protein content of TMPs from control and irradiated
cells (Fig. 1a). Furthermore, comparisons between the
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Fig. 1 TMPs from cells exposed to radiation contain distinct immu-
nomodulatory proteins. a TMPs were collected from untreated (con-
trol) or 2 Gy irradiated (RT) EMT/6 or PyMT cells. Protein content
was characterized by mass spectrometry analysis. Principal component
analysis shows clear separation between the control and irradiated
samples. b, c Heatmap (left) and volcano plot (right) for the com-
parison between TMPs from the control and irradiated EMT/6 (b) or
PyMT (c) cells. d EMT/6, PyMT, 4T1, E0771, and DA3 breast car-
cinoma cell cultures were irradiated once at the indicated radiation
doses. Forty-eight hours later, the percentages of PD-L1-expressing
cells and PD-L1-positive TMPs were assessed by flow cytometry (n=
3 biological repeats). ***p < 0.001 (for cells) and #p < 0.05; ##p < 0.01;
###p < 0.001 (for TMPs) as assessed by two-tailed Student’s t test (for
b, c) or one-way ANOVA followed by Tukey post hoc test (for d)
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proteomes of TMPs derived from the control and
radiotherapy-exposed EMT/6 and PyMT cells revealed over
480 and 300 significantly altered proteins, respectively, as
calculated by Student’s t test, FDR 0.05, and S0= 0.1, as
previously described [34] (Fig. 1b, c; Tables S2, S3). Among
the immune-related proteins enriched in TMPs from irra-
diated cells were Hspd1, caveolin 1, AKT1, and complement
component protein (C1qbp) in EMT/6 TMPs, and peroxir-
edoxin 2 in PyMT TMPs, all of which are associated with the
suppression of T-cell activation and proliferation (Fig. 1b, c;
Tables S4, S5). Furthermore, Fisher’s exact test demonstrated
a significant enrichment of various distinct processes such as
regulatory, biosynthetic, metabolic, and enzymatic processes
in TMPs from radiotherapy-treated cells, in both cell types
tested (Tables S6, S7). Altogether, these results suggest that
the protein expression pattern in TMPs from radiated breast
cancer cells is associated with immune modulation.
Recent studies have demonstrated that extracellular
vesicles derived from cancer cells exhibit extensive immu-
nosuppressive activity, an effect mediated by PD-L1
[26, 27]. We therefore investigated the expression level of
PD-L1 in our system, comparing between untreated and
radiated cells as well as TMPs derived from these cells.
Since PD-L1 expression was below the detection threshold
in our mass spectrometry analysis, we employed flow-
cytometry analysis using anti-PD-L1 antibodies. In PyMT
and E0771 cell lines, radiation resulted in an increase in the
percentage of PD-L1-positive cells, an effect that was not
apparent in DA3, 4T1, and EMT/6 cells. Importantly, there
was an increase in the percentage of PD-L1-expressing
TMPs derived from EMT/6, PyMT, and E0771 but not 4T1
and DA3 cells exposed to different doses of radiotherapy,
when compared to TMPs from untreated cells (Figs. 1d and
S3A). Notably, up to 80% of TMPs derived from radiated
PyMT cells were positive for PD-L1. Importantly, although
the percentage of TMPs expressing PD-L1 was increased,
the expression intensity of PD-L1 on these TMPs was not
elevated (Fig. S3B), indicating that it is more likely the
distribution of PD-L1 on TMPs’s membrane rather than
increased production of PD-L1. Consistently, in vivo ana-
lysis of TMPs in breast carcinoma tumor-bearing mice
exposed to a single dose 2 Gy radiation revealed a sig-
nificant increase in the percentage of PD-L1-expressing
TMPs (Fig. S3C). Collectively, these results demonstrate
that radiotherapy affects the percentage of PD-L1-
expressing TMPs originating from different breast cancer
cells both in vitro and in vivo.
TMPs derived from irradiated breast carcinoma cells
inhibit cytotoxic T-cell activity
PD-L1 binds to PD-1 expressed by several types of immune
cells and negatively regulates the activity of cytotoxic
T cells [35]. Our proteomic characterization of TMPs ori-
ginating from irradiated cells suggests that TMPs may play
a role in immunomodulation following exposure to radia-
tion. We therefore sought to investigate the immunomo-
dulatory suppression activity of TMPs. We focused on
EMT/6 and PyMT cells as they exhibited the highest per-
centage of TMPs expressing PD-L1 in response to radio-
therapy. As a negative control, we chose to work with
4T1 cells, as they produced low levels of PD-L1-positive
TMPs, regardless of radiation. PD-L1 knockout was per-
formed in the three cell lines using CRISPR-Cas9 as
described in the Materials and methods section. The lack of
PD-L1 expression in EMT/6, PyMT, and 4T1 cells was
verified by flow cytometry (Fig. S4). To evaluate the effect
of PD-L1-positive TMPs on T-cell activation, TMPs were
isolated from untreated or irradiated WT and PD-L1 KO
EMT/6, PyMT, and 4T1 tumor cell cultures and mixed with
splenocytes freshly extracted from spleens of non-tumor-
bearing BALB/c or C57Bl/6 mice. The samples were then
applied to a T-cell activation kit, and the activation of
cytotoxic T cells was monitored by flow cytometry. TMPs
isolated from 2 Gy irradiated WT EMT/6 or PyMT cultures
inhibited cytotoxic T-cell activation in comparison with
TMPs isolated from untreated cultures. However, this
inhibitory effect was not apparent with TMPs isolated from
PD-L1 KO EMT/6 or PyMT cultures (Fig. 2a). Of note,
TMPs isolated from WT or PD-L1 KO 4T1 cells had no
effect on T-cell activation, regardless of whether they were
isolated from untreated or irradiated cells (Fig. S5A). These
results can be further explained by a 6.56-fold increase in a
ratio between PD-L1-positive EMT/6-derived TMPs and
activated CD8 T cells (when comparing irradiated to
untreated groups), whereas in 4T1 there was almost no
change in the same ratio (Table S8). Lastly, the levels of
granzyme B in the conditioned medium of splenocytes co-
cultured with TMPs from WT or PD-L1 KO EMT/6, PyMT,
and 4T1 cells were consistent with results obtained in the T-
cell activation assay (Figs. 2b and S5B). Overall, these
findings demonstrate that PD-L1-positive TMPs, which are
generated from irradiated cells, play a role in suppressing
cytotoxic T-cell activity in vitro.
Next, to evaluate the immunesuppressive effects of
TMPs in vivo, a classic immunological WINN assay was
performed, as described in the Materials and methods sec-
tion. Briefly, splenocytes from naive mice were mixed with
EMT/6 or PyMT cells in a 100:1 ratio and co-implanted into
the mammary fat pad of naive mice. In some groups, TMPs
from control or 2 Gy irradiated cells were mixed with tumor
cells and splenocytes, and subsequently co-implanted into
the mammary fat pad of naive mice. Mice implanted with
EMT/6 or PyMT cells alone or mice co-implanted with
activated splenocytes obtained from tumor-bearing mice
were used as a negative and positive control, respectively.
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These experiments were performed in immune-
compromised mice (SCID or sub-lethally irradiated mice)
in order to eliminate the intrinsic immune responses that
take place in immunocompetent mice. Mice co-injected
with TMPs originating from 2 Gy irradiated cells exhibited
the highest tumor growth rate in both EMT/6 and PyMT
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models, demonstrating that the TMPs may play a role in
immune nodulation (Fig. 2c). Subsequent analysis of
cytotoxic T cells in extracted tumors revealed that TMPs
from 2 Gy irradiated cells significantly reduced the per-
centage of CD8-positive cells and their activation state (Fig.
2d). Notably, the percentage of MDSCs and macrophages in
both EMT/6 and PyMT tumors remained unchanged, sug-
gesting that they do not play a role in our experimental
setting (Fig. S6). Taken together, TMPs originating from
irradiated cells contribute to immunosuppression activity, in
part by inhibiting cytotoxic CD8+ T cells.
TMPs derived from irradiated breast carcinoma cells
promote tumor growth and inhibit T-cell activity
in vivo
To characterize the in vivo effects of TMPs, we first inves-
tigated whether TMPs derived from irradiated cultures affect
tumor growth in orthotopic tumor models in mice. To this
end, mice were orthotopically implanted with EMT/6, PyMT,
or 4T1 cells. When tumors reached a size of ~100mm3, the
mice were intravenously injected with the respective TMPs
(1 × 105 per injection) derived from untreated or irradiated
cultures. Tumor growth was monitored twice weekly until
one of the groups reached end point. Tumor growth was
enhanced in mice injected with TMPs derived from 2Gy
irradiated EMT/6 and PyMT cultures in comparison with all
other groups, while not always significantly. In contrast,
TMPs derived from untreated or irradiated 4T1 cultures had
no noticeable effect on tumor growth (Figs. 3a and S7A). At
end point, tumors were excised, prepared as single-cell sus-
pensions and analyzed by flow cytometry to quantify the
level of activated cytotoxic T cells. We found that injecting
EMT/6 or PyMT tumor-bearing mice with TMPs derived
from 2Gy irradiated cell cultures reduced the number of
activated cytotoxic T cells (CD8+/CD25+ cells) in tumors
compared with control groups, whereas their numbers in 4T1
tumors were unaffected. The level of activated cytotoxic
T cells was also reduced in the spleen and to a lesser extent in
peripheral blood of EMT/6 and PyMT, but not 4T1 tumor-
bearing mice in response to TMP injections (Figs. 3b–d and
S7B–D). Taken together, these results suggest a possible
link between TMP-mediated immunomodulation and tumor
progression in vivo.
TMPs derived from irradiated tumor cells are
distributed in the spleen and liver, but not in lymph
nodes and kidney
To gain further insight into which organs are involved in the
immunomodulatory role of peripheral blood circulating
TMPs in vivo, we focused on the distribution pattern of
TMPs in various peripheral blood cell-infiltrating organs.
To this end, 8–10-week-old BALB/c mice were intrave-
nously injected with PKH26-fluorescently labeled TMPs
derived from untreated or 2 Gy irradiated EMT/6 cultures.
After 24 h, the mice were sacrificed, and spleens, livers,
kidneys, and axillary lymph nodes were processed for
immunostaining and flow-cytometry analysis. TMPs accu-
mulated in large numbers in the spleen and liver, but were
hardly detected in the kidney and lymph nodes (Fig. 4a–c).
Importantly, neither the distribution pattern nor the accu-
mulation of TMPs was affected by exposure to radiation.
These results suggest that TMPs shed from cells located at
the primary tumor act not only locally at the tumor site but
also systemically when distributed through peripheral
blood, but such effects are not modified in response to
radiotherapy. By colonizing distant organs such as the
spleen and liver, the TMPs have the potential to modulate
the activity of immune cells at these remote organ sites. Yet,
their immunomodulatory effects do not necessary involve
lymph nodes.
TMPs derived from irradiated cells counteract T cell-
mediated inhibition of tumor growth
To further explore the possible link between TMP-mediated
immunomodulation and tumor progression, we performed a
T-cell adoptive transfer experiment. To this end, CD8+
T cells were isolated from spleens of EMT/6 and PyMT
tumor-bearing mice. The CD8+ cells were then cultured for
24 h either alone or in the presence of TMPs derived from
untreated or irradiated EMT/6 or PyMT cultures. Subse-
quently, the CD8+ cells from each group were intravenously
injected into SCID mice or sub-lethally irradiated C57Bl/6
Fig. 2 TMPs shed from irradiated EMT/6 and PyMT cells inhibit
cytotoxic T-cell activity. a Splenocytes isolated from naïve 8–10-week-
old BALB/c mice were cultured with CD3+/CD28+ T-cell activating
beads in the absence (baseline) or presence of TMPs derived from the
control or irradiated WT EMT/6 or PyMT cells or their PD-L1 KO
counterparts as indicated. Negative control (NC) refers to cultures in the
absence of activation beads. Twenty-four hours later, the splenocytes
were harvested and the percentage of activated cytotoxic T cells (CD8
+/CD25+) was evaluated by flow cytometry. b Granzyme B levels in
the conditioned medium of the cultures described in (a) were assessed
by specific ELISA. The results represent three biological repeats. c, d
Eight to 10-week-old SCID and 6 Gy sub-lethally irradiated C57Bl/6
mice (n= 5 mice/group) were implanted with EMT/6 or PyMT cells
mixed with splenocytes from untreated (naive) mice in a 1:100 ratio. In
addition, in some groups, these samples were mixed with TMPs ori-
ginated from control or 2 Gy irradiated cells, and subsequently injected
into mice. A mixture of EMT/6 or PyMT cells with activated spleno-
cytes from tumor-bearing mice were used as a positive control. EMT/6
and PyMT implanted to the mammary fat pad alone were used as
negative control. Tumor growth was assessed twice weekly (c). At end
point, tumors were extracted and the percentage of the total and acti-
vated CD8 cells (CD8+/CD25+) was evaluated by flow cytometry (d).
*p < 0.05, **p < 0.01, ***p < 0.001, as assessed by one-way ANOVA
followed by Tukey post hoc test
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mice bearing 200 mm3 EMT/6 and PyMT tumors, respec-
tively. Of note, in the PyMT model, all mice including the
control group were equally irradiated to avoid any possible
additive effect of radiation. The adoptive transfer was
repeated weekly, and tumor growth was monitored until one
of the groups reached end point. As expected, mice that
received CD8+ cells from tumor-bearing mice exhibited a
slower tumor growth rate in comparison with mice that
received T cells from naive mice. Importantly, tumor growth
rate was accelerated in mice that received CD8+ cells that
Fig. 3 TMPs from irradiated EMT/6 or PyMT cells promote tumor
growth and inhibit cytotoxic T-cell activity in vivo. a EMT/6 or PyMT
tumor cells (5 × 105/mouse) were orthotopically implanted into the
mammary fat pad of 8–10-week-old female BALB/c and C57Bl/6
mice, respectively (n= 4–5 mice/group). When tumors reached
~100 mm3, mice were either intravenously injected with PBS (control)
or TMPs derived from control or 2 Gy irradiated EMT/6 or PyMT cells
every 3 days (indicated by arrows, 1 × 105 TMPs/mouse). Tumor
volume was monitored twice weekly. b–d At end point, blood was
drawn, and tumors and spleens were harvested. The percentage of
activated CD8 cells (CD8+/CD25+) was evaluated in tumors (b),
spleens (c), and peripheral blood (d) by flow cytometry. *p < 0.05,
**p < 0.01, as assessed by one-way ANOVA followed by Tukey post
hoc test
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were pre-cultured with TMPs derived from irradiated EMT/6
or PyMT cultures. In contrast, mice that received CD8+ cells
pre-cultured with TMPs derived from untreated cultures
exhibited tumor growth rate similar to mice that received
T cells from tumor-bearing mice (Fig. 5a). At end point,
tumors and spleens were harvested and prepared as single-
cell suspensions for the evaluation of CD8+ T cells by flow
cytometry. The percentage of total CD8+ cells and the
activated fraction of CD8+CD25+ cells were both reduced in
the spleens of PyMT and EMT/6 tumor-bearing mice treated
with TMPs from irradiated cells, although such results did
not reach statistical significance in the EMT/6 model
(Fig. 5b). Similarly, injection of TMPs from irradiated cells
resulted in a significant reduction of activated CD8+ cells in
PyMT tumors, whereas no significant differences were
detected between any of the groups in EMT/6 tumors (Fig.
S8). It is plausible that the nonsignificant results in T-cell
activity found in the EMT/6 tumor model is due to the time
gap between the last T-cell injection and the end point of the
experiment. Specifically, in the EMT/6 model, analysis was
performed 7 days after the last T-cell adoptive transfer,
whereas in the PyMT tumor model the tumors were har-
vested 3 days after T-cell adoptive transfer. Collectively, our
results demonstrate that TMPs originating from irradiated
tumor cells inhibit cytotoxic T-cell activity, and as such
accelerate tumor growth.
Fig. 4 TMPs from irradiated breast carcinoma cells accumulate in
spleen and liver. a TMPs shed from untreated (control) or 2 Gy irra-
diated EMT/6 cells were labeled with PKH26, a membrane fluorescent
linker. The fluorescently labeled TMPs (1 × 105 TMPs/mouse) were
intravenously injected into naive 8–10-week-old BALB/c mice (n=
3–4 mice/group). Control mice were injected with PBS. After 24 h, the
indicated organs were homogenized, and the percentage of PKH26+
cells (cells presumably fused with TMPs) and PKH26-labeled TMPs
from the total microparticles (MPs) in the supernatant were evaluated
by flow cytometry. b Shown are representative flow cytometry dot
plots of PKH26-labeled TMPs from the total MPs in the spleen, liver,
kidney, and axillary lymph nodes of mice injected with PBS (control)
or TMPs from untreated (control) or irradiated cells. c Sections of the
spleen, liver, kidney, and axillary lymph nodes from mice described in
(a) after they were injected with TMPs from irradiated EMT/6 cells
were stained with DAPI and analyzed by fluorescent microscopy.
Representative images are shown. Magnification ×1000 field view;
scale bar = 20 µm. *p < 0.05 (for spleen), $p < 0.05 and $$p < 0.01 (for
liver), as assessed by one-way ANOVA followed by Tukey post
hoc test
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Blocking the PD-1–PD-L1 axis alleviates TMP-
mediated inhibition of cytotoxic T-cell activity
Immune checkpoint therapy has been shown clinically to
dramatically induce cytotoxic activity of CD8+ T cells
toward malignant cells in certain cancer types. Such therapy
is currently standard of care for the treatment of several
malignancies [35]. Furthermore, some early-phase clinical
studies have revealed that the combination of radiation with
immune checkpoint therapy improves therapeutic outcome
[16, 17]. Our aforementioned results demonstrate that TMPs
originating from irradiated tumor cells can inhibit cytotoxic
T-cell activity, in part via PD-L1, whereas TMPs from
untreated cells that minimally express PD-L1 have no such
effect. We therefore asked whether blocking PD-L1 on
irradiated TMPs would alleviate the inhibitory effect of
TMPs on T-cell-mediated killing of tumor cells. To this
end, CD8+ cells isolated from the spleens of EMT/6 or
PyMT tumor-bearing mice were cultured with TMPs
derived from WT and PD-L1 KO untreated or irradiated
EMT/6 and PyMT tumor cells, respectively. In some
groups, PD-L1 expressed on TMPs was pharmacologically
neutralized with anti-PD-L1 antibody. The T cells were then
washed to remove free TMPs and then used in a T-cell
killing assay performed on EMT/6 or PyMT cells. As
expected, and specifically at the 3 h time point, TMPs from
Fig. 5 Pre-exposure of cytotoxic T cells to TMPs from irradiated cells
counteracts T-cell-mediated inhibition of tumor growth. Spleens of
8–10-week-old naive or EMT/6 or PyMT tumor-bearing mice (BALB/c
and C57Bl/6 mice, respectively) were harvested and prepared as
single-cell suspensions from which CD8+ cells were isolated by
negative selection. CD8+ cells originating from the tumor-bearing
mice were cultured for 24 h either alone (activated CD8) or with TMPs
from control EMT/6 or PyMT cells (activated CD8 + TMP control) or
2 Gy irradiated EMT/6 and PyMT cells (activated CD8 + TMP 2 Gy).
CD8+ cells from each group were intravenously injected into EMT/6
tumor bearing 8–10-week-old female SCID mice or PyMT tumor-
bearing 6 Gy sub-lethally irradiated C57Bl/6 mice (106 cells/mouse,
n= 5 mice/group). Control mice were injected with PBS (untreated).
a Adoptive transfer of CD8+ cells was performed weekly at the
indicated time points (arrows) until end point. Tumor growth was
assessed every other day. b At end point, spleens were removed and
prepared as single-cell suspensions for the evaluation of the total CD8
+ cells and activated T cells (CD8+/CD25+) by flow cytometry. *p <
0.05, **p < 0.01, ***p < 0.001, as assessed by one-way ANOVA
followed by Tukey post hoc test
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2 Gy irradiated cells significantly attenuated T-cell killing of
cancer cells, compared with activated CD8 cells or T cells
pre-cultured with control TMPs. In addition, PD-L1 KO
TMPs from irradiated cells did not induce an inhibitory
effect in both cell lines. Similarly, pre-culturing TMPs from
irradiated cells with anti-PD-L1 antibodies partially restored
the T-cell killing activity of CD8+ cells (Fig. 6a–d). Fur-
thermore, in an in vivo experiment, the combination of anti-
PD-1 therapy with a single dose 2 Gy radiation in mice-
bearing EMT/6 tumors resulted in greater tumor growth
delay than any of the monotherapy arms (Fig. S9). Overall,
these results may provide a possible explanation for the
improved therapeutic effect of blocking the PD-L1 immune
checkpoint in combination with radiation. They suggest that
such enhanced therapeutic activity might be the result of, at
least in part, the expression of PD-L1 on TMPs, the effect of
which leads to reduced T-cell cytotoxicity and subsequent
tumor progression.
Discussion
Immune checkpoint inhibitor therapy represents a major
advancement in cancer treatment, leading to improved
response in several cancer types. However, such therapy
was found to be beneficial for only a small proportion of
patients for reasons that are not fully clear [36]. In this
study, we evaluate the immunomodulatory effects of
radiation with a specific emphasis on TMPs. In our
experimental setting, we used previous published methods
to extract TMPs. Their physical characterization has been
previously described [19, 28–33]. Next, we demonstrate
that TMPs shed from cells exposed to radiotherapy com-
prise proteins with immunomodulatory and immunosup-
pressive activities when compared with TMPs from
untreated cells. These results prompted us to evaluate the
expression of known immunomodulatory proteins, such as
PD-L1, on TMPs. Our study demonstrates that in response
to radiation the percentage of TMPs expressing PD-L1
originating from breast carcinoma cells may increase;
however, this effect is tumor dependent. We show that
EMT/6 and PyMT cells shed a higher percentage of PD-
L1-positive TMPs in response to radiation in comparison
with TMPs of 4T1, E0771, and DA3 cells. The 2 Gy and
6 Gy radiation doses caused distinct effects in several cell
lines tested. For example, the 6 Gy dose did not increase
the number of PD-L1 expressing TMPs derived from
EMT/6 cells. On the contrary, in E0771 cells, 6 Gy
radiation increased the percentage of PD-L1-positive
TMPs, an effect that was not observed after 2 Gy irra-
diation. These differential effects might be explained by
differences in stress response mechanisms and activation
of transcription machinery in the distinct cell types
[37, 38]. Importantly, we demonstrate that these effects
can modulate cytotoxic T-cell activity in distant organs
such as the spleen, and therefore can systemically promote
immune escape. Indeed, it has been shown that radio-
therapy, in some cases, affects tumor growth in part by
modulating the immune system, both within and outside of
the irradiation field.
The abscopal effect—a systemic off target therapeutic
effect of local radiation—may be explained in part by the
presence of tumor cell debris that boosts the immune sys-
tem, leading to improved therapeutic outcome [4, 10, 39]. In
addition, radiotherapy induces the expression of pro-
inflammatory cytokines, such as CXCL9, CXCL10,
CXCL11, and CXCL16, which enhance the chemotaxis of
T cells into tumors and increase their ability to mediate
cytotoxicity [40, 41]. Our study demonstrates that radiation
inhibits the activity of T cells by various immunomodula-
tory proteins, such as Hspd1, caveolin 1, AKT1, comple-
ment component 1 Q subcomponent-binding protein
(C1qbp), and peroxiredoxin 2 (Tables S4, S5). In addition
to these proteins, we found that also the percentage of
TMPs from cells exposed to radiation express PD-L1. The
finding that the distribution of PD-L1 expression is mod-
ified in response to radiation provides a rationale to com-
bine radiation with immunomodulatory drugs, which is
currently being evaluated in the clinical setting [16–18]. In
this regard, in a prospective analysis of melanoma patients
treated with CTLA-4 and radiation, a subset of patients
benefited from the combinatorial therapy [42]. Furthermore,
preclinical studies have indicated that the expression of PD-
L1 on the cell surface of tumor cells is altered in response to
radiation, thereby potentially contributing to the immuno-
modulation activity of radiotherapy [43, 44]. Thus, radiation
may have both pro-tumorigenic and anti-tumorigenic
activities within the tumor site, which may sometimes
explain limited response to radiotherapy. In this regard, the
basic immunosuppressive effects we report in this study
were induced by a single dose 2 Gy radiation, which is
considered to be a maximal daily dose in most hyper-
fractionation protocols. We chose to work with such a dose
in our experimental setting in order to avoid tumor cell
death and apoptotic bodies which could affect our TMP
data. However, in the clinic, cancer patients may receive
cumulative doses of 40–80 Gy in hyperfractionation radio-
therapy. Therefore, immunosuppressive tumor activity
should be further evaluated with repeatable doses of
radiation in clinical samples.
EVs affect a variety of cellular and molecular pathways
not only in cancer but also in other physiological and
pathological conditions [20]. In cancer, tumor-derived
EVs transfer oncogenes between tumor cells, mobilize
cells that promote tumor growth and metastasis, and
contribute to the formation of pre-metastatic niches
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[21, 22, 45], an effect which can be augmented in response
to chemotherapy [25]. Moreover, it has been recently
demonstrated that EVs possess an additional role of
mediating immune evasion of the tumor through the
PD-L1–PD-1 axis. Specifically, EVs originating from
stem-like cells of glioblastoma overexpress PD-L1. A
correlation with primary tumor volume was found to be
associated with T-cell inhibition by such EVs, resulting in
Fig. 6 TMP-mediated inhibition of cytotoxic T-cell activity is partially
dependent on the PD-1-PD-L1 axis. a–d CD8+ cells were isolated
from the spleens of EMT/6 or PyMT tumor-bearing mice (activated
CD8). The CD8+ cells were cultured with TMPs from untreated
(activated CD8+TMP control) or 2 Gy irradiated WT or PD-L1 KO
EMT/6 or PyMT cells (activated CD8+TMP 2 Gy and activated CD8
+KO TMP 2 Gy groups, respectively). In addition, CD8+ cells were
cultured with TMPs extracted from 2 Gy irradiated WT EMT/6 or
PyMT cells, in the presence of anti-PD-L1 antibody (10 µg/ml)
(activated CD8+TMP 2 Gy+αPD-L1). Twenty-four hours later, CD8+
cells were washed and then used in a T-cell killing assay performed on
EMT/6 (a) or PyMT (b) cells, as a function of propidium iodide (PI)
staining (n= 5 biological repeats). EMT/6 or PyMT cells cultured
alone served as a negative control (untreated). Representative micro-
graphs at the 12 h time point are shown (c). A T-cell killing assay at
the 3 h time point is presented by a bar graph (d). *p < 0.05, ***p <
0.001 using one-way ANOVA followed by Tukey post hoc test
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the increased aggressiveness of the tumor [26]. In another
study, EVs from melanoma cells were found to express
PD-L1. The percentage of exosomes expressing PD-L1 in
peripheral blood of advanced melanoma patients corre-
lated with disease progression [27]. Here, we specifically
show that TMPs can modulate the immune response to
radiotherapy. Proteomic analysis revealed that proteins
such as Hspd1, caveolin 1, AKT1, complement compo-
nent 1 Q subcomponent-binding protein (C1qbp), and
peroxiredoxin 2 are highly expressed in TMPs from cells
exposed to radiation in comparison with TMPs from
control cells. While PD-L1 was under the detection level
of the mass cytometry analysis in our experimental setting,
we chose to focus on PD-L1 due to its known immuno-
modulatory properties [46]. It must be noted that proteins
other than PD-L1 probably play significant roles in
immunomodulation and should be further evaluated in
additional studies. Indeed, the inhibition of PD-L1 by
genetic or pharmacological approaches did not completely
inhibit T-cell activity, further indicating that other
immunomodulatory proteins expressed by TMPs affect T-
cell activity in our experimental setting. Focusing on PD-
L1, we demonstrate that the percentage of TMPs origi-
nating from certain irradiated breast cancer cells is
increased. Furthermore, we demonstrate that these PD-L1-
positive TMPs promote tumor growth due to the inhibition
of cytotoxic T cells. Our results therefore explain, in part,
the synergistic benefit of combining radiotherapy with PD-
1–PD-L1 blockade.
In summary, the combination of radiotherapy with
immunomodulatory drugs has been shown to improve
therapeutic benefit at least in preclinical models and some
clinical studies. Yet, the underlying mechanisms described
thus far, have been mostly associated with abscopal effects.
Here, we demonstrate that TMPs originating from irradiated
cells express various immunomodulatory proteins, includ-
ing PD-L1. These TMPs home to the spleen, and conse-
quently reduce systemic cytotoxic T-cell activity. These
effects can explain the pro-tumorigenic activity of TMPs
following radiation, also described in other studies [5, 10].
Accordingly, we therefore suggest that evaluating the
expression of PD-L1 specifically on circulating TMPs in
cancer patients who undergo radiotherapy, may serve as a
possible biomarker for successful combination of radio-
therapy with immune checkpoint inhibition.
Materials and methods
Cell lines
EMT/6, 4T1, and E0771 murine breast carcinoma cell lines
and MBA-MB-231 human breast carcinoma cells were
purchased from the American Type Culture Collection
(ATCC, Manassas, VA, USA) or CH3 Biosystems (Amherst,
NY, USA), and were used within 6 months of resuscitation.
PyMT murine breast carcinoma cell line was derived from
primary tumor-bearing transgenic mice expressing polyoma
middle T-antigen (PyMT) under the control of the murine
mammary tumor virus (MMTV) promoter [47]. DA3 mam-
mary adenocarcinoma cells were originally derived from the
D1-DMBA-3 transplantable mammary tumors [48]. EMT/6,
PyMT, DA3, and MDA-MB-231 cells were grown in the
Dulbecco's modified Eagle's medium (DMEM, Sigma-
Aldrich, Israel), and 4T1 and E0771 cells were grown in the
Roswell Park Memorial Institute medium (RPMI, Sigma-
Aldrich). All cell lines were supplemented with 10% fetal calf
serum (FCS), 1% L-glutamine, 1% sodium pyruvate, and 1%
penicillin–streptomycin–neomycin in solution (10 mg/ml,
Biological Industries, Israel), and were cultured at 37 °C in
5% CO2. The cells were routinely tested as mycoplasma free.
Generation of PD-L1 KO cells
A 24-base-pair gRNA sequence (CACCGGTC-
CAGCTCCCGTTCTACA) targeting exon 3 of PD-L1 was
cloned into pSpCas9(BB)-2A-GFP(PX458) (Addgene
plasmid #48138) according to Ran et al. [49] to obtain
pSpCas9-GFP-PD-L1. Consequently, EMT/6, PyMT, and
4T1 cells were electroporated with pSpCas9-GFP-PD-L1.
After 48 h, GFP-positive cells were sorted, and single-cells
were plated in 96-well plates using FACSAria™ IIIu sorter
instrument (BD Bioscience, San Jose, CA, USA). PD-L1
expression of expanded colonies was measured by flow
cytometry. Clones showing complete loss of PD-L1 were
further confirmed by Sanger sequencing of exon 3 of PD-
L1. The original cell cultures were pooled and used as WT
control.
Generation and collection of TMPs
Tumor cells (as indicated in the text) were cultured until
they reached 80% confluency, at which point, the medium
was replaced with serum-free (SF) medium. Subse-
quently, cells were exposed to ionizing radiation, using a
linear accelerator 6 MeV electron beam using Elekta
Precise (Elekta, Sweden) at a dose rate of 40 cGy per
minute, for a total dose of 2 Gy or 6 Gy at room tem-
perature as a single fraction (Department of Radiotherapy,
Rambam Medical Center, Haifa, Israel). Control cells
were not exposed to radiation. To collect TMPs origi-
nating from the cells, conditioned medium (CM) was
collected 48 h post radiation and centrifuged at 3300×g
for 20 min at room temperature to remove floating cells.
The cell-free supernatants were then centrifuged at
20,000 × g for 1 h at 4 °C to precipitate TMPs. The pellet
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was re-suspended in phosphate buffer solution (PBS),
divided into small aliquots, and stored at −80 °C until
further use. In some experiments, TMPs were extracted
from blood as previously described [19].
Mass spectrometry and proteomic analysis of TMPs
TMPs were subjected to proteomic analysis at the Smoler
Protein research center (Technion). The extracted TMP
pellets were re-suspended in 8M Urea, 100 mM ammonium
bicarbonate, and sonicated. The proteins were reduced with
3 mM DTT for 30 min at 60 °C, modified with 9 mM
iodoacetamide in 100 mM ammonium bicarbonate in the
dark for 30 min at room temperature, and digested in 2M
Urea, 25 mM ammonium bicabonate with modified trypsin
(Promega, Madison, WI, USA) at a 1:50 enzyme-to-
substrate ratio, overnight at 37 °C. An additional trypsini-
zation was performed for 4 h. The resulting tryptic peptides
were desalted using C18 tips (Harvard Apparatus, Hollis-
ton, MA, USA) dried and re-suspended in 0.1% formic acid.
Samples were analyzed by LC–MS/MS using an Q Exactive
plus mass spectrometer (ThermoFisher Scientific, Waltham,
MA, USA) fitted with a capillary HPLC (easy nLC 1000,
ThermoFisher Scientific). The peptides were loaded onto a
C18 homemade capillary column (20 cm, 75 micron ID)
packed with Reprosil C18-Aqua (Dr Maisch GmbH, Ger-
many) in solvent A (0.1% formic acid in water). The pep-
tides mixture was resolved with a (5–28%) linear gradient
of solvent B (95% acetonitrile with 0.1% formic acid) for
120 min followed by 10 min gradient at 28–95% and 25 min
at 95% acetonitrile with 0.1% formic acid in water at flow
rates of 0.15 μl/min. Mass spectrometry was performed in a
positive mode (m/z 350–1800, resolution 70,000) using
repetitively full MS scan followed by collision induces
dissociation (HCD, at 35 normalized collision energy) of
the 10 most dominant ions (>1 charges) selected from the
first MS scan. A dynamic exclusion list was enabled with
exclusion duration of 20 s.
The mass spectrometry data were analyzed using the
MaxQuant software 1.5.2.8 for peak picking identification
and quantitation using the Andromeda search engine,
searching against the mouse uniprot database with mass
tolerance of 20 ppm and 4.5 ppm after calibration. Oxida-
tion on methionine and protein N-terminus acetylation were
accepted as variable modifications, and carbamidomethyl
on cysteine was accepted as static modifications. Minimal
peptide length was set to seven amino acids, and a max-
imum of two miscleavages were allowed. Peptide- and
protein-level false discovery rates (FDRs) were filtered to
1% using the target-decoy strategy. Protein tables were
filtered to eliminate the identifications from the reverse
database, and common contaminants and single-peptide
identifications. The data were quantified by label-free
analysis using the same software, based on extracted ion
currents (XICs) of peptides enabling quantitation from each
LC/MS run for each peptide identified in any of experi-
ments. The protein groups output was further analyzed
using the Perseus 1.5.0.31 software [50]. Label-free quan-
tification (LFQ) intensity values [51] were log2 transformed.
Each comparison (EMT/6 control vs radiation or PyMT
control vs radiation) was processed separately, following
data filtration that kept only proteins that were quantified in
at least two of the three replicates in at least one of the
sample groups. Student’s t test was performed with
permutation-based FDR correction with a cutoff of 0.05 and
S0 correction of 0.1 [34]. Enrichment analysis was carried
out using Fisher’s exact test with FDR cutoff of 0.02. PCA
was performed following data imputation, by replacing the
missing values with values that form a normal distribution
with a downshift of 1.6 standard deviations and width of 0.4
of the original data distribution.
Analysis of TMP number and size
TMPs quantification was performed using flow cytometry
as previously described [31]. Briefly, 0.78 µm-sized beads
(Bangs Laboratories, Inc., IN, USA) were used to gate the
TMPs’ size, and the ratio between TMP number and
counting beads (Bangs Laboratories, Inc.) was calculated.
In some experiments, size characterization of TMPs was
performed using NanoSight NS300 (Malvern, UK) and
NanoSight NS300 NTA v2.3 software (Malvern, UK).
Animal models
All animal studies and animal experimental protocols were
approved by the Animal Care and Use Committee of the
Technion. EMT/6 or 4T1 cells (5 × 105) were orthotopically
implanted into the mammary fat pad of 8–10-week-old
female BALB/c mice (Envigo, Israel). PyMT cells (5 × 105)
were orthotopically implanted into the mammary fat pad of
8–10-week old female C57Bl/6 mice (Envigo, Israel).
MDA-MB-231 cells (2 × 106) were orthotopically implan-
ted into the mammary fat pad of 8–10-week-old female
SCID mice (Envigo, Israel). In most experiments, n= 5
mice/group were used, unless otherwise indicated. In all
experiments, mice were randomly assigned to experimental
groups. All irradiation procedures, tumor inoculations, and
injections of TMPs were performed blindly. Tumor volume
was measured using Vernier calipers and calculated by the
formula width × width × length × 0.5. When tumors reached
100 mm3, the mice were intravenously injected with 1 × 105
TMPs derived from EMT/6, PyMT, or 4T1 cells (in 100 μl
of PBS). Control mice were injected with PBS. In some
experiments, when tumors reach 100–200 mm3, the mice
were exposed to a single dose 2 Gy radiation (locally) and
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were also treated with anti-PD-1 (100 μg/mouse, twice
weekly), or its IgG control. Peripheral blood was collected
48 h following irradiation from retro-orbital sinus bleed, and
TMPs were isolated for further analysis as described in ref.
[19]. When tumors reached end point (usually
1000–1500 mm3) mice were killed, and tumors, spleens,
and blood were collected for further analysis as indicated in
the article.
For the T-cell adoptive transfer experiment, spleens were
harvested from 500 mm3 EMT/6 and PyMT tumor-bearing
or naive mice, and subsequently prepared as single-cell
suspension to extract splenocytes, as previously described
[52]. CD8+ cells were then isolated from the splenocyte
suspensions by negative selection using MojoSortTM mouse
CD8 T-cell isolation kit (BioLegend, San Diego, CA, USA)
in accordance with the manufacturer’s instruction. CD8+
cells from tumor-bearing mice were incubated for 24 h at
37 C° with or without TMPs obtained from 2 Gy irradiated
or control EMT/6 or PyMT cells (1 × 105 TMPs/1 × 106
CD8+ cells), and afterwards were washed to remove free
TMPs. Next, the CD8+ cells were intravenously injected
into orthotopically implanted 10-week-old SCID mice-
bearing 100–200 mm3 EMT/6 tumors or 10-week-old
C57Bl/6 mice sub-lethally irradiated (6 Gy total body
radiation, at a dose rate of 125 cGy per min) bearing
100–200 mm3 PyMT tumors. This adoptive T-cell transfer
was repeated once a week. At end point, mice were killed,
and tumors and spleens were harvested for further analysis
as described below.
The WINN assay was performed as previously described
[53, 54]. Briefly, spleens were collected from naive mice or
500 mm3 EMT/6 or PyMT tumor-bearing mice. Subse-
quently, they were prepared as single-cell suspension to
obtain splenocytes. The splenocytes from naive mice were
mixed with EMT/6 or PyMT cells in a ratio of 100:1 (50 ×
106 splenocytes/0.5 × 106 EMT/6 or PyMT cells) as well as
with TMPs (1 × 105) extracted from naive or 2 Gy irradiated
EMT/6 or PyMT cells. The mixture of cells and TMPs was
subcutaneously injected to the flanks of 8–10-week old
SCID mice (for EMT/6 tumors) and sub-lethally irradiated
C57Bl/6 (for PyMT tumors). The mixture of activated
splenocytes from tumor-bearing mice and tumor cells was
used as a positive control. Tumor growth was monitored
regularly. At end point, tumors were resected, processed for
single-cell suspension, and analyzed for T-cell activity.
Evaluation of cytotoxic T-cell activity and cancer cell
killing
Cytotoxic T-cell activity was evaluated using a mouse T-
cell activation kit (Miltenyi Biotec, Germany) in accordance
with the manufacturer’s instructions. Briefly, splenocytes
(106) from naive BALB/c or C57Bl/6 mice were cultured
for 24 h at 37 °C in the presence or absence of anti-mouse
CD3ε, and CD28 biotinylated beads (106 beads/sample) in
the presence or absence of TMPs originating from EMT/6
or PyMT cells. The beads mimic antigen-presenting cells
and activate resting T cells. Subsequently, cells were cen-
trifuged at 470 × g for 5 min at room temperature. Cell
pellets were re-suspended in PBS, and the levels of total
CD8+ T cells and activated T cells (CD8+/CD25+) were
quantified by flow cytometry as described below. In paral-
lel, granzyme B secretion was evaluated by quantifying its
level in the supernatants of the spleen and tumor cells using
specific ELISA (R&D Systems, Minneapolis, MN, USA),
in accordance with the manufacturer’s instructions.
For the T-cell killing assay, CD8+ cells were isolated by
negative selection from splenocyte suspensions derived
from the spleens of EMT/6 or PyMT tumor-bearing mice,
using MojoSortTM mouse CD8 T cell isolation kit (BioLe-
gend, San Diego, CA, USA), in accordance with the man-
ufacturer's instructions. The CD8+ cells were then cultured
for 24 h at 37 °C in the presence or absence of TMPs from
untreated or 2 Gy irradiated EMT/6 or PyMT cells (WT or
PD-L1 KO cells). For pharmacological PD-L1 inhibition,
10 µg/ml anti-mouse PD-L1 antibody (BioXCell, West
Lebanon, NH; cat. BP0101) was added. Subsequently, the
T cells were washed with PBS to remove free TMPs and
unbound antibodies and then cultured with EMT/6 or
PyMT cells for 24 h in a ratio of 10:1 (25,000–2500 cells).
Propidium iodide (PI, 500 nM) was added to cultures in
order to identify dead cells. T-cell killing effect was mon-
itored using Incucyte Zoom HD/2CLR system (Essen
BioScience, Ann Arbor, MI). All experiments were per-
formed in triplicates using at least three biological repeats.
Flow-cytometry acquisition and analysis
Single-cell suspensions prepared from tumor, spleen, or
peripheral blood cells as previously described [52], were
immunostained with antibodies purchased from BioLegend
(BLG, San Diego, CA) or BD Biosciences (BD, Franklin
Lakes, NJ) in accordance with the manufacturers’ instruc-
tion. The following marker combinations were used to
define total T cells (CD8+, cat. BLG-100714), activated
cytotoxic T lymphocytes (CD8+, cat. BLG-100714/CD25+,
cat. BD-102007), myeloid-derived suppressor cells (MDSC,
CD11b+, cat. BLG-101230/Gr-1+, cat. BD-108408), and
macrophages (F4/80+, cat. BLG-123116). TMPs derived
from the control, or radiotherapy-treated murine breast
cancer cells were immunostained and analyzed for PD-L1
expression. In peripheral blood samples obtained from
mice, TMPs derived from MDA-MB-231 tumors were
identified by immunostaining for human leukocyte antigen
(HLA, cat. BD-311406) and analyzed for human PD-L1
expression (cat. BD-329706). Similarly, breast carcinoma
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cells and their derived TMPs were analyzed for PD-L1
expression (cat. BD-124312). Annexin V and 7-
aminoactinomycin D (7-AAD) were used to distinguish
between live, early apoptotic, late apoptotic, and dead cells,
as previously described [55]. In some experiments, TMPs
were labeled with PKH26 fluorescent cell linker (Sigma-
Aldrich, St. Louis, MO, USA) in accordance with the
manufacturer's instructions. These PKH26-tagged TMPs or
cells with which they fused were identified as a positive
event. At least 200,000 events were acquired using an
LSRFortessa flow analyzer system (BD Bioscience, San
Jose, CA, USA) or CyAN ADP flow cytometer (Beckman
Coulter, CA, USA) followed by analysis using the FlowJo
7.6.1 software (FlowJo, LLC, Ashland, OR, USA).
Immunostaining
Spleens, livers, kidneys and lymph nodes were embedded in
OCT (Tissue-Tek, Sakura Finetek USA Inc., Randor, PA,
USA) and stored at −80 °C until further processed. Next,
tissues were cryosectioned (10 μm) using Leica CM1950
Clinical Cryostat (Leica Biosystems, Germany). Sections
were fixed with 4% paraformaldehyde at 4 °C for 30 min,
stained with 4'-6-Diamidino-2-phenylindole (DAPI) (Elec-
tron Microscopy Sciences, Hatfield, PA, USA) to stain
nuclei and analyzed using an inverted fluorescent micro-
scope Leica CTR 6000 microscope system (Leica Micro-
systems, Germany) per ×100 objective field.
Statistical analysis
To ensure the adequate power of the results all experiments
were performed at least in two technical triplicates and three
biological repeats. In some experiments, mice that exhibited
pathological conditions which are not related to the
experiment were excluded from the analyses. All experi-
ments were performed in a randomized manner. The ana-
lysis of the results was performed blindly. The data are
presented as mean ± standard deviation (SD). Statistically
significant differences were assessed by one-way ANOVA,
followed by Tukey post hoc test (when comparing between
more than two groups) using GraphPad Prism 4 software
(La Jolla, CA, USA). When applicable, estimate of variance
was performed and statistical significance comparing only
two sets of data were determined by two-tailed Student’s t
test. Significance was set at values of p < 0.05, and desig-
nated as follows: *p < 0.05; **p < 0.01; ***p < 0.001.
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